Screener
Castle Biosciences CSTL Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| ASSETS | March 31, 2026 / (unaudited) | December 31, 2025 |
|---|---|---|
| Current Assets | ||
| Cash and cash equivalents | $63,764 | $116,729 |
| Marketable investment securities | 197,921 | 182,776 |
| Accounts receivable, net | 42,264 | 43,382 |
| Inventory | 10,461 | 10,254 |
| Prepaid expenses and other current assets | 14,491 | 7,956 |
| Total current assets | 328,901 | 361,097 |
| Long-term accounts receivable, net | 1,921 | 1,878 |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's accounts receivable?
- Castle Biosciences (CSTL) reported accounts receivable of $42.26M in Q1 2026.
- How has Castle Biosciences's accounts receivable changed year-over-year?
- Castle Biosciences's accounts receivable decreased by 25.0% year-over-year, from $56.35M to $42.26M.
- What is the long-term trend for Castle Biosciences's accounts receivable?
- Over 5 years (2020 to 2025), Castle Biosciences's accounts receivable has grown at a 27.7% compound annual growth rate (CAGR), from $12.76M to $43.38M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about Castle Biosciences's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude